Exhibit 99.1
Stevanato Group Appoints Franco Stevanato Chief Executive Officer,
Succeeding Franco Moro
PIOMBINO DESE, Italy May 28, 2024 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug
delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new
Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Companys Board of Directors.
Franco Stevanato commented, On behalf of the Board of Directors and the Company, I would like to express my sincere gratitude to
Mr. Moro for his valuable contributions to Stevanato Group. Over the last five years, Franco has played a pivotal role in helping to guide the Company through the challenges of the global COVID-19
pandemic, expand our global industrial footprint to meet rising customer demand, and drive global standardization of our manufacturing sites to improve operational efficiencies.
I am honored to have served as Chief Executive Officer and grateful for having been part of the Companys evolution, said
Franco Moro. I believe the business fundamentals are strong and the Company will leverage on everything we have accomplished and started in recent times. I wish Franco Stevanato the best as he continues to lead the Company to further success,
after years of hard work carried out together, while I will continue to serve the Company as director.
Mr. Stevanato has held
the position of Executive Chairman since 2021 and he previously served as Chief Executive Officer of Stevanato Group from 1998 to 2021. He is the driving force behind the Groups long-term strategic vision and integrated value proposition.
Mr. Stevanato is responsible for leading the Companys global expansion over the last two decades, expanding the Companys diversified product portfolio, establishing the Groups science-based technology excellence centers,
enhancing its research and development capabilities, and leading the Company through its initial public offering.
Fabrizio Bonnani,
Stevanato Groups lead independent director, commented, We thank Franco Moro for his dedicated service to the Company as Chief Executive Officer. Looking ahead, Franco Stevanato is a strategic leader who has navigated the Company through
periods of growth and investment. He embodies the core principles and values of Stevanato Group, and the Board is confident that Franco Stevanato is well positioned to advance the Companys strategic imperatives and drive long-term shareholder
value.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions as well as
engineering solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the entire drug life cycle from development to clinical and commercial stages. Stevanato Groups core capabilities in scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its ability to offer value added solutions to clients.